Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.32 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.32 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23345349 | 0.86 | CYP1A2 (0.43) | CYP1A2TDP1SMN1; SMN2KDM4EPIK3CD | |
| SCHEMBL3401340 | 0.85 | CYP1A2 (0.56) | CYP1A2TDP1SMN1; SMN2KDM4ERAB9A | |
| SCHEMBL15776315 | 0.78 | RAB9A (0.36) | KDM4ERAB9ADPP4DPP7 | |
| SCHEMBL11339464 | 0.76 | RIPK1 (0.34) | RAB9ADPP4DPP7ALDH1A1 | |
| SCHEMBL11408269 | 0.76 | ALDH1A1 (0.39) | RAB9ACHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL6052873 | 0.73 | — | — | |
| Trifluoroacetic Acid SCHEMBL29695782 | 0.73 | CYP1A2 (0.43) | CYP1A2TDP1SMN1; SMN2KDM4ERAB9A | |
| SCHEMBL13634259 | 0.73 | CHRNB2 (0.42) | TDP1KDM4ECHRNB2CHRNA3CHRNA4 | |
| SCHEMBL24010073 | 0.71 | CYP1A2 (0.52) | CYP1A2TDP1SMN1; SMN2KDM4EPIK3CD | |
| SCHEMBL9829530 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2373634-B1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARM CO LTD (JP) | 2015-11-11 | — | — | EP | disclosed |
| US-7825155-B2 | Oxindole derivative as feeding control agent | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-11-02 | — | — | US | disclosed |
| US-7825155-B2 | Oxindole derivative as feeding control agent | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-11-02 | — | — | US | disclosed |
| WO-2009067541-A2 | INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-05-28 | — | — | WO | disclosed |
| US-20090131398-A1 | OXINDOLE DERIVATIVE AS FEEDING CONTROL AGENT | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090131398-A1 | OXINDOLE DERIVATIVE AS FEEDING CONTROL AGENT | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| EP-1935883-A1 | OXINDOLE DERIVATIVE AS FEEDING CONTROL AGENT | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131398-A1 | OXINDOLE DERIVATIVE AS FEEDING CONTROL AGENT | GPR119, OXTR, CCKAR | CYP1A2 712/4885TDP1 4846/4885SMN1; SMN2 2771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.